Mycobacterium tuberculosis and rifampin resistance, United Kingdom.

File Description SizeFormat 
Mycobacterium tuberculosis and rifampin resistance, United Kingdom..pdfPublished version232.81 kBAdobe PDFView/Open
Title: Mycobacterium tuberculosis and rifampin resistance, United Kingdom.
Authors: Sam, IC
Drobniewski, F
More, P
Kemp, M
Brown, T
Item Type: Journal Article
Abstract: The United Kingdom Health Protection Agency Mycobacterium Reference Unit offers a national Fastrack molecular service for detecting Mycobacterium tuberculosis complex (MTBC) and rifampin resistance by using the INNO-LiPA Rif.TB assay. We analyzed the service in a routine, nontrial context of 1,997 primary clinical specimens, including 658 nonrespiratory specimens. The overall adjusted concordance, sensitivity, specificity, positive predictive value, and negative predictive value for detecting MTBC were 91.2%, 85.2%, 96.2%, 95.7%, and 86.7%, respectively (unadjusted, 86.7%, 85.2%, 88.2%, 86.9%, and 86.7%), when false-positive samples from patients (n = 83) with a known microbiologic diagnosis of MTBC or patients receiving current or recent antituberculous treatment were excluded. The parameters for detecting rifampin resistance were 99.1%, 95.0%, 99.6%, 92.7%, and 99.7%, respectively. The assay enabled earlier diagnosis of MTBC and rifampin resistance (15.2 days) compared with culture-based techniques (30.7 days).
Issue Date: 1-May-2006
ISSN: 1080-6040
Start Page: 752
End Page: 759
Journal / Book Title: Emerg Infect Dis
Volume: 12
Issue: 5
Copyright Statement: © 2006 the Author(s). Sam I-C, Drobniewski F, More P, Kemp M, Brown T. Mycobacterium tuberculosis and rifampin resistance, United Kingdom. Emerg Infect Dis. 2006 May.
Conference Place: United States
Appears in Collections:Department of Medicine
Faculty of Medicine

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons